Dermatology News

Dermatology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Arnold AW et al. - The authors report the first treatment of metastasized RDEB-SCC with the epidermal growth factor receptor antagonist cetuximab (Erbitux). The response was favourable, and adverse events were similar to those in patients without EB. Notably, no additional negative cutaneous effects, such as severer skin or mucosal blistering, occurred.

Related Articles

A case of epidermolysis bullosa acquisita with unusual clinical features
Clinical and Experimental Dermatology, 10/16/09    Relevance Score: 68%

Successful radiation therapy for supratentorial primitive neuroectodermal tumor and epidermolysis bullosa simplex
Pediatric Blood & Cancer, 10/07/09    Relevance Score: 64%

Study of relationship of concha bullosa to nasal septal deviation and sinusitis
Indian Journal of Otolaryngology and Head & Neck Surgery, 10/01/09    Relevance Score: 42%

Today in Autoimmune/Bullous Dz...keeping you current

Case of autoimmune progesterone dermatitis presenting as fixed drug eruption
Journal of Dermatology, 12/08/09

Genetic basis of oculocutaneous albinism
Expert Review of Dermatology, 12/07/09

Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease?
Journal of the European Academy of Dermatology and Venereology, 12/04/09

Today in Dermatologic Oncology...keeping you current

Basal cell carcinoma arising on a chronic lymphedematous leg
Journal of Dermatology, 12/08/09

Adult T-cell leukemia-lymphoma associated with follicular mucinosis
Journal of Dermatology, 12/08/09

Therapy of Sezary syndrome
Expert Review of Dermatology, 12/07/09